Cormorant Asset Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Cormorant Asset Management’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-896,600	Closed	-$2.41M	–	98
2016 Q1	$2.41M	Hold	896,600	–	–	0.36%	60
2015 Q4	$2.77M	Hold	896,600	–	–	0.33%	55
2015 Q3	$3.96M	Hold	896,600	–	–	0.63%	43
2015 Q2	$5.12M	Hold	896,600	–	–	0.68%	41
2015 Q1	$8.03M	Buy	896,600 +821,600	+1,095%	+$6.6M	1.24%	24
2014 Q4	$425K	Buy	+75,000	New	+$392K	0.07%	67

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cormorant Asset Management's EPRS Position: Q2 2016 in Review

Cormorant Asset Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2016, closing a stake of 896,600 shares — an estimated $2.41M sold.

Cormorant Asset Management first reported a position in EPRS in Q4 2014 and held it in 6 quarters. The position peaked at $8.03M in Q1 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

Cormorant Asset Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Cormorant Asset Management sold 896,600 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2016, an estimated $2.41M.
Cormorant Asset Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014 and held it in 6 quarters.
Cormorant Asset Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $8.03M in Q1 2015.
32 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2016.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.